The emerging field of molecular information and genomic analysis play an increasingly important role for future medicine and diagnostics solutions, in particular for cancer patients. As a leader in both pharmaceuticals and diagnostics, Roche is committed to deepening our understanding of the biology of cancer to develop tests and treatments that may help tailor medicines for patients. Our aim of personalised healthcare is to follow the progression of science to deliver practice-changing diagnostics and medicines that transform the lives of individual patients.
In Australia, Roche’s pharmaceutical division is the licensed distributor of FoundationOne®CDx and FoundationOne®Heme, offering comprehensive genomic profiling (CGP) services and decision support tools that may inform clinical care in cancer.
Healthcare Professionals wanting more information about Foundation Medicine services may go to www.rocheinteract.com.au or phone Roche (Pharmaceuticals) Medical Information on 1800 233 950. Patients wanting more information about cancer tumour testing should speak with their healthcare professionals.